 |
|
A Call for Fairness in Formulary Decisions
Arch Intern Med. 2006;166:16-18.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
In this issue of the ARCHIVES, Morgan DeWitt and colleagues1 demonstrate that an irrational prescription drug reimbursement policy (Medicare reimburses infliximab and not etanercept, even though etanercept is more convenient and less expensive) leads to undesirable clinical practice (Medicare patients are 30% more likely to receive infliximab than privately insured patients). Others2-3 have also shown that poor formulary decisions can lead to poor outcomes, yet drug formularies are increasingly seen by payors of prescription drugs as an essential aspect of drug policy.4-5 Why? In this editorial, we briefly describe the rationale for formularies and discuss aspects that are receiving increasing attention: the availability of information about the benefits and harms of drugs, how to involve the public in these difficult decisions, and the price of drugs.
A drug formulary is a list of drugs that a private or public insurance scheme will pay for. Drugs not on the . . . [Full Text of this Article]
AUTHOR INFORMATION
Wendy Levinson, MD;
Andreas Laupacis, MD
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLE
Medicare Coverage of Tumor Necrosis Factor  Inhibitors as an Influence on Physicians’ Prescribing Behavior
Esi Morgan DeWitt, Henry A. Glick, Daniel A. Albert, Marshall M. Joffe, and Frederick Wolfe
Arch Intern Med. 2006;166(1):57-63.
ABSTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
What Interventions Should Pharmacists Employ to Impact Health Practitioners' Prescribing Practices?
Grindrod et al.
The Annals of Pharmacotherapy 2006;40:1546-1557.
ABSTRACT
| FULL TEXT
|
